- Home
- PHIO vs PTIX Comparison
PHIO vs PTIX Comparison
Compare PHIO & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHIO
- PTIX
- Stock Information
- Founded
- PHIO 2011
- PTIX 1994
- Country
- PHIO United States
- PTIX United States
- Employees
- PHIO N/A
- PTIX N/A
- Industry
- PHIO Biotechnology: Pharmaceutical Preparations
- PTIX Biotechnology: Pharmaceutical Preparations
- Sector
- PHIO Health Care
- PTIX Health Care
- Exchange
- PHIO Nasdaq
- PTIX Nasdaq
- Market Cap
- PHIO 3.4M
- PTIX 3.7M
- IPO Year
- PHIO N/A
- PTIX 2016
- Fundamental
- Price
- PHIO $2.77
- PTIX $0.44
- Analyst Decision
- PHIO Strong Buy
- PTIX
- Analyst Count
- PHIO 1
- PTIX 0
- Target Price
- PHIO $36.00
- PTIX N/A
- AVG Volume (30 Days)
- PHIO 18.5M
- PTIX 377.2K
- Earning Date
- PHIO 11-14-2024
- PTIX 11-14-2024
- Dividend Yield
- PHIO N/A
- PTIX N/A
- EPS Growth
- PHIO N/A
- PTIX N/A
- EPS
- PHIO N/A
- PTIX N/A
- Revenue
- PHIO N/A
- PTIX N/A
- Revenue This Year
- PHIO N/A
- PTIX N/A
- Revenue Next Year
- PHIO N/A
- PTIX N/A
- P/E Ratio
- PHIO N/A
- PTIX N/A
- Revenue Growth
- PHIO N/A
- PTIX N/A
- 52 Week Low
- PHIO $1.53
- PTIX $0.43
- 52 Week High
- PHIO $10.35
- PTIX $1.87
- Technical
- Relative Strength Index (RSI)
- PHIO 50.99
- PTIX 39.26
- Support Level
- PHIO $2.41
- PTIX $0.43
- Resistance Level
- PHIO $4.53
- PTIX $0.52
- Average True Range (ATR)
- PHIO 0.83
- PTIX 0.05
- MACD
- PHIO 0.12
- PTIX -0.01
- Stochastic Oscillator
- PHIO 14.18
- PTIX 6.74
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.